CD20-Positive Neoplastic Cells Present: Clinical Trials

1 trial for CD20-Positive Neoplastic Cells Present, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 withdrawn. 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 21Withdrawn 1

Follow CD20-Positive Neoplastic Cells Present: new trials by email Literature Review of CD20-Positive Neoplastic Cells Present trials Research Report on CD20-Positive Neoplastic Cells Present

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma
Dexamethasone, Ibrutinib, Lenalidomide - CCND1 Positive, CD20-Positive Neoplastic Cells Present
Phase 2WithdrawnM.D. Anderson Cancer Center2019-07-012019-08-22

Narrower conditions

Lymphoma, Mantle-Cell (1)

Broader conditions

Hemic and Lymphatic Diseases (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Lymphatic Diseases (1)  ·  Lymphoma (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphoproliferative Disorders (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)

Interventions

CT-P10 (1)  ·  Calcium Dobesilate (1)  ·  Dexamethasone (1)  ·  Lenalidomide (1)  ·  Rituximab (1)  ·  auricularum (1)  ·  dexamethasone 21-phosphate (1)  ·  dexamethasone acetate (1)  ·  ibrutinib (1)

Sponsors

M.D. Anderson Cancer Center (1)

NIH funding

P30CA016672 (1)